The use of intermediate-purity clotting factor concentrates and HIV disease progression in men with haemophilia

Haemophilia

Volumn 2, Issue 2, 1996, Pages 78-81

  Sabin, C A ^a   Pasi, J ^a   Phillips, A N ^a   Lilley, P ^a   Elford, J ^a   Lee, C A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

AIDS; Clotting factor concentrate; Haemophilia; HIV

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DISEASE COURSE; DRUG PURITY; HEMOPHILIA; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0029979447     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.1996.tb00019.x     Document Type: Article

References (24)

1. Seremetis S, Aledort LM, Bergman G, Bona R, Bray G, Brettler D, et al. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet, 1993; 342: 700-3.
2. de Biasi R, Rocino A, Miraglia E, Mastrullo L, Quirino AA. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomised, prospective, two-year comparison with an intermediate purity concentrate. Blood, 1991; 78: 1919-22.
3. UK Regional Haemophilia Centre Directors Committee. Recommendations on choice of therapeutic products for the treatment of patients with haemophilia A, haemophilia B and von Willebrands Disease. Blood Coagul Fibrinolysis, 1992; 3: 205-14.
4. Goedert JJ, Cohen AR, Kessler CM, Eichinger S, Seremetis SC, Rabkin CS, et al. Risks of immunodeficiency, AIDS and death related to purity of factor VIII concentrate. Lancet, 1994; 344: 791-2.
5. Montoro JB, Oliveras J, Lorenzo JI, Tusell JM, Altisent C, Molina R, et al. An association between clotting factor concentrates use and mortality in human immunodeficiency virus-infected hemophilic patients. Blood, 1995; 86: 2213-9.
6. Sabin C, Pasi J, Phillips AN, Elford J, Janossy G, Lee C. CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients. Throm Haem, 1994; 72: 214-7.
7. Lee CA, Phillips AN, Elford J, Miller EJ, Bofill M, Griffiths PD, et al. The natural history of human immunodeficiency virus infection in a haemophilic cohort. Brit J Haematol, 1989; 73: 228-34.
8. Sabin C, Phillips AN, Elford J, Griffiths P, Janossy G, Lee C. The progression of HIV disease in a haemophilic cohort followed for 12 years. Brit J Haematol, 1993; 83: 330-3.
9. Bofill M, Janossy G, Lee CA, MacDonald-Burns D, Phillips AN, Sabin C, et al. Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol, 1992; 88: 243-52.
10. Lee CA, Phillips AN, Elford J, Janossy G, Griffiths P, Kernoff P. Progression of HIV disease in a haemophilic cohort followed for 11 years and the effect of treatment. Brit Med J, 1991; 303: 1093-6.
11. Phillips AN, Lee CA, Elford J, Janossy G, Timms A, Bofill M, et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet, 1991; 337: 389-92.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc, 1958; 53: 457-81.
13. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman and Hall, 1984.
14. SAS Institute Inc. SAS/STAT User's Guide, Version, 6, 4th edn. Cary, NC: SAS Institute Inc., 1989.
15. Margolick JB, Volkman DJ, Folks TM, Fauci AS. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. J Immunol, 1987; 138: 1719-23.
16. Gowda SD, Stein BS, Mohagheghpour N, Benike CJ, Engleman EG. Evidence that T cell activation is required for HIV-1 entry in CD4+ lymphocytes. J Immunol, 1989; 142: 773-80.
17. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS, et al. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science, 231: 850-3.
18. Biagiotti R, Giudizi MG, Almerigogna F, Mazzetti M, Alessi A, Del Prete GF, et al. Abnormalities of in vitro immunoglobulin production in apparently healthy haemophiliacs: relationship with alterations of T cell subsets and with HTLV-III seropositivity. Clin Exp Immunol, 1986; 63: 354-8.
19. Ragni MV, Ruben FL, Winkelstein A, Spero JA, Bontempo FA, Lewis JH. Antibody responses to immunization of patients with hemophilia with and without evidence of human immunodeficiency virus (human T-lymphotropic virus type III) infection. J Lab Clin Med, 1987; 109: 545-9.
20. Matheson DS, Green BJ, Fritzler MJ, Poon MC, Bowen TJ, Hoar DL. Humoral immune response in patients with hemophilia. Clin Immunol Immunopathol, 1987; 44: 41-50.
21. Yarchoan R, Venzon DJ, Pluda JM, Lietzau J, Wyvill KM, Tsiatis AA, et al. CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Int Med, 1991; 115: 184-9.
22. Phillips AN, Elford J, Sabin C, Bofill M, Janossy G, Lee CA. Immunodeficiency and the risk of death in HIV infection. JAMA, 1992; 268: 2662-6.
23. Pasi KJ, Sabin C, Lee CA, Hill FGH. Effect of intermediate purity factor VIII concentrate treatment 1980-90 in a cohort of HIV infected haemophilic patients. Thromb Haem, 1993; 69: 856 (abstract).
24. Gjerset GF, Pike MC, Mosley JW, Hassett J, Gletcher MA, Donegan E, et al. Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Blood, 1994; 5: 1666-71.